Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals

Executive Summary

GlaxoSmithKline's delisting of three Paxil patents will clear the way for approval of generic versions of the antidepressant, and set up a potential dispute over how 180-day exclusivity will be awarded

Related Content

Synthon Pexeva To Launch At 20% Discount To Generic Paxil; GSK Suit Settled
GSK/Par Paxil Generic Deal Upheld In Court; FTC Closes Patent Investigation
Generic Paxil Approved By FDA; Apotex Faces Tricky Launch Decision
Generic Paxil Launches Unlikely This Year, Par Says; Court, FDA Issues
Generic paroxetine exclusivity
Early Paxil Competitor? FDA Approves Synthon’s Paroxetine 505(b)(2)
Paxil Delisting: Will Appellate Case On FDA Patent Listing Role Be Moot?
Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says
Purepac Gabapentin 180-Day Exclusivity Award “Reasonable,” Judge Says
Apotex Paxil ANDA: Presence Of Hemihydrate Does Not Infringe GSK’s Patent



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts